Drug solutions Promex and Realeve honored by MedTech Breakthrough for standout achievement in pain management
In the realm of medical technology, Pulsante is making waves as a groundbreaking solution for chronic pain and neurological disorders. This drug-free, safe, and effective treatment option, developed by Realeve, has been clinically proven in over 700 patients and boasts FDA Breakthrough Device designation.
Dr. Peter Bonutti, the founder and CEO of Realeve, asserts that Pulsante changes the way we approach chronic pain and neurological disorders. The Pulsante RC-200 handheld device powers the implant, offering the potential to treat a range of brain-related conditions.
The MedTech Breakthrough Awards program, recognizing the top companies, technologies, and products in the global health and medical technology market, has honoured Pulsante. The system provides relief for patients suffering from conditions such as chronic migraine and neuropathic pain.
Pulsante features a minimally invasive battery-free wireless compact SPG microstimulation implant. The header assembly of Pulsante is sealed inside a ceramic/titanium encasement, ensuring safety and durability.
Dr. Bonutti, with over 30 years of experience, 500+ patents, and a history of involvement in other groundbreaking medtech, expects future iterations of the technology to incorporate AI-based pain tracking and predictive analytics.
In addition to pain management, Pulsante may be used to treat other conditions linked to nerve dysfunction, such as sleep disorders and anxiety. Realeve's Pulsante has been awarded the 2025 Best New Pain Management Technology Solution by Promex, a company that manufactured a critical part of the Pulsante device.
The latest advancements in micro-neurostimulation for treating central nervous system (CNS) disorders emphasize high-density neural interfacing devices, precision neuromodulation techniques, and microscale surgical robotics. These advancements contribute to improved chronic pain management and neurological function restoration.
Although specific details on Pulsante's micro-neurostimulation technology and its direct impact on chronic pain management remain limited, Pulsante is known for its implantable microdevice platform tailored for chronic pain management. This approach typically involves modulating peripheral nerves or dorsal root ganglia to provide targeted pain relief with minimal invasiveness, offering alternatives to systemic medications.
Pulsante offers patients greater independence and improves quality of life by improving healthcare delivery, reducing reliance on medications, and providing a more holistic treatment approach. As more clinical data becomes available, we can expect a deeper understanding of Pulsante's role in revolutionizing chronic pain management across various neurological conditions.
- Pulsante, a revolutionary drug-free treatment developed by Realeve, focuses on managing chronic pain and neurological disorders, particularly chronic migraine and neuropathic pain, a fact confirmed by the MedTech Breakthrough Awards.
- The Pulsante RC-200 handheld device powers an implant, providing potential relief for a variety of brain-related conditions, including neurological disorders.
- The minimally invasive and battery-free wireless compact SPG microstimulation implant of Pulsante is sealed inside a ceramic/titanium encasement, enhancing safety and durability.
- Dr. Bonutti, a seasoned medtech expert with over 30 years of experience, aims to incorporate AI-based pain tracking and predictive analytics in future versions of the Pulsante technology.
- Beyond pain management, Pulsante may offer solutions for other conditions linked to nerve dysfunction, such as sleep disorders and anxiety.
- With facilities like Promex manufacturing critical parts of the Pulsante device and advancements in micro-neurostimulation technology, we can anticipate the restoration of neurological function and improved chronic pain management.
